Abstract
Diabetes is a common and important complication of cystic fibrosis, an autosomal recessive genetic disease due to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Cystic fibrosis-related diabetes (CFRD) is associated with profound detrimental effects on the disease course and mortality and is expected to increase in prevalence as the survival of patients with cystic fibrosis continues to improve. Despite progress in the functional characterization of CFTR molecular defects, the mechanistic basis of CFRD is not well understood, in part because of the relative inaccessibility of the pancreatic tissue and the limited availability of representative animal models. This review presents a concise overview of the current understanding of CFRD pathogenesis and provides a cutting-edge update on novel findings from human and animal studies. Potential contributions from paracrine mechanisms and β-cell compensatory mechanisms are highlighted, as well as functional β-cell and α-cell defects, incretin defects, exocrine pancreatic insufficiency, and loss of islet cell mass. State-ofthe- art and emerging treatment options are explored, including advances in insulin administration, CFTR modulators, cell replacement, gene replacement, and gene editing therapies.
Original language | English (US) |
---|---|
Pages (from-to) | 1386-1400 |
Number of pages | 15 |
Journal | Journal of the Endocrine Society |
Volume | 1 |
Issue number | 11 |
DOIs | |
State | Published - Jan 1 2017 |
Keywords
- Beta cell
- CFRD
- CFTR
- Cystic fibrosis
- Diabetes
- Pancreatic insufficiency
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism